HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Chervu, L. R. Articles by Blaufox, M. D. Search for Related Content PubMed PubMed Citation Articles by Chervu, L. R. Articles by Blaufox, M. D.

Use of ^99mTc-Cu-DTPA Complex as a Renal Function Agent

Albert Einstein College of Medicine, Bronx, New York

Correspondence: For reprints contact: L. Rao Chervu, Nuclear Medicine Div., Albert Einstein College of Medicine, Yeshiva University, Eastchester Rd. & Morris Park Ave., Bronx, NY 10461.

ABSTRACT

The use of cuprous ion as a reducing agent for pertechnetate is described for the first time. The potential usefulness of a ^99mTc-Cu-DTPA complex as a renal function agent was evaluated by organ distribution studies in animals and by simultaneous continuous-infusion and single-injection clearance studies. Radioiodinated iothalamate was used as a standard for the measurement of GFR. The ratio for the clearance with the new copper complex to that with iothalamate is close to unity, both for continuous infusion (0.97 ± 0.01 s.e.) and for single injection (1.05 ± 0.03). The coefficients of correlation are similarly close to unity: 0.96 and 0.99, respectively. Dialysis of plasma samples obtained after injection of ^99mTc-Cu-DTPA into bilaterally nephrectomized rats indicates that only small amounts (<4%) of the complex are protein-bound. These data and the low toxicity of the copper preparation in animals appear to justify its investigation for kidney function measurement and imaging in man as well as its use as a GFR agent in animal studies.